SGLT2 inhibitors reduced the risk of all-cause mortality in women with HFpEF (HR 0.66) while no effect was observed in men (HR 1.06).
Heart failure with preserved ejection fraction (HFpEF)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Cardiovascular mortality and heart failure hospitalization — HR 0.66 (0.48-0.90)
Effect estimate: HR 0.66 (95% CI 0.48-0.90)
Abstract Diastolic dysfunction of the left ventricle (LVDD) is equally common in elderly women and men. LVDD is a condition that can remain latent for a long time but is also held responsible for elevated left ventricular filling pressures and high pulmonary pressures that may result in (exercise-induced) shortness of breath. This symptom is the hallmark of heart failure with preserved ejection fraction (HFpEF) which is predominantly found in women as compared to men within the HF spectrum. Given the mechanistic role of LVDD in the development of HFpEF, we review risk factors and mechanisms that may be responsible for this sex-specific progression of LVDD towards HFpEF from an epidemiological point-of-view and propose future research directions.
Building similarity graph...
Analyzing shared references across papers
Loading...
Anne Margje Lisa Naomi van Ommen
University Medical Center Utrecht
Elisa Dal Canto
Heart Failure & Transplant
Maarten J. Cramer
Cardiac Imaging
BMC Medicine
Utrecht University
University Medical Center Utrecht
Building similarity graph...
Analyzing shared references across papers
Loading...
Ommen et al. (Tue,) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors was evaluated on Cardiovascular mortality and heart failure hospitalization (HR 0.66, 95% CI 0.48-0.90). SGLT2 inhibitors reduced the risk of all-cause mortality in women with HFpEF (HR 0.66) while no effect was observed in men (HR 1.06).
synapsesocial.com/papers/69619aca1b8549878d87c956 — DOI: https://doi.org/10.1186/s12916-022-02650-4